Anthracycline cardiotoxicity in long-term survivors of childhood cancer

  title={Anthracycline cardiotoxicity in long-term survivors of childhood cancer},
  author={Rebecca E Scully and Steven E. Lipshultz},
  journal={Cardiovascular Toxicology},
Anthracycline chemotherapy is a widely-used and effective treatment for a wide spectrum of childhood cancers. Its use is limited by associated progressive and clinically significant cardiotoxic effects. Onset can be acute, early, or late. While acute onset is rare, long-term survivors have significantly elevated rates of cardiac morbidity and mortality. Major complications include cardiomyopathy, coronary artery disease, and atherosclerosis. Means of prevention and treatment continue to be… 
Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
This systematic review aims to summarize how aerobic exercise can help to alleviate unintended cardiotoxic side effects and identify gaps in need of further research.
Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity
A general overview of cardiotoxicity is provided focusing on the effect of anthracyclines and their epigenetic molecular mechanisms on cardiot toxicity.
New developments in anthracycline-induced cardiotoxicity.
This review discusses recent developments in the molecular mechanisms underlying anthracycline-induced cardiotoxicity, focusing on controversial aspects and on recent data regarding analogues of the natural compounds, tumor-targeted formulations and cardioprotective agents.
Cardiovascular effects of systemic cancer treatment.
Early Detection and Prediction of Cardiotoxicity - Biomarker and Echocardiographic Evaluation
The time from early development of cardiac dysfunction to the modification or end of chemotherapy and beginning of heart failure therapy, is an important determinant of the extent of recovery and the need for a realtime diagnosis of cardiac injury represents the main goal for cardiologists and oncologists.
Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
This study shows that anthracycline treatment is associated with acute and chronic neurohumoral activation of cardiac dysfunction that is manifested by a significant increase in NT-proBNP, and suggests that NT- ProBNP could be useful in the early detection of anthrACYcline cardiotoxicity.
The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma
A comparable efficacy and reduced cardiotoxicity even in frail and elderly patients have been shown with the use of non-pegylated liposomal doxorubicin in standard chemotherapy regimens for NHL, and the goal will be to apply these advancements to the treatment of patients with NHL.
P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.
Data support a model wherein a p53-dependent cardioprotective pathway, mediated via STAT3 activation, mitigates DOX-induced myocardial stress during drug delivery and suggest an explanation as to how p53 inhibition can result in cardioprotsection during drug treatment and, paradoxically, enhanced cardiotoxicity long after the cessation of drug treatment.
Cardiac damage in anthracyclines therapy: focus on oxidative stress and inflammation.
The present review aimed to discuss ANTs-induced cardiac injury from different points of view, updating and focusing on oxidative stress and inflammation, since these pathways are not exclusive or independent from each other but they together importantly contribute to the complexity of AN Ts-induced multifactorial cardiotoxicity.


Epidemiology of anthracycline cardiotoxicity in children and adults.
Although anthracycline chemotherapy has improved overall survivorship of patients with cancer, there is a significant risk of cardiotoxicity associated with this class of drugs.
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
The most promising current strategies to limit or prevent anthracycline‐induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening are summarised.
Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
  • K. Nysom, K. Holm, S. Lipshultz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
Depressed left ventricular fractional shortening andleft ventricular dilatation were uncommon years after treatment of childhood leukemia when cumulative anthracycline doses were < or = 300 mg/m2.
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
Doxorubicin therapy in childhood impairs myocardial growth in a dose-related fashion and results in a progressive increase in left ventricular afterload sometimes accompanied by reduced contractility, hypothesized to result in inadequateleft ventricular mass and clinically important heart disease in later years.
Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
Female sex and a higher rate of administration of doxorubicin were independent risk factors for cardiac abnormalities after treatment with doxorbicin for childhood cancer; the prevalence and severity of abnormalities increased with longer follow-up.
Cardiac safety of liposomal anthracyclines.
Early results of clinical trials suggest that combining trastuzumab or a taxane with NPLD or PLD instead of a conventional anthracycline significantly reduces cardiotoxicity risk without reducing chemotherapeutic efficacy.
Long-term effects of treatments for childhood cancers
The high frequency, delayed onset, and potential severity of late effects demand increased and lifelong monitoring of these individuals and a multidisciplinary approach to long-term care of these patients.
Cardioprotective interventions for cancer patients receiving anthracyclines.
It is concluded that if the risk of cardiac damage is expected to be high, it might be justified to use dexrazoxane in patients with cancer treated with anthracyclines, however, for each individual patient clinicians should weigh the cardioprotective effect of dexraz oxane against the possible risk of a lower response rate.
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
In high-risk, HDC-treated patients, defined by an increased troponin I value, early treatment with enalapril seems to prevent the development of late cardiotoxicity.
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
An overview of issues confirms that anthracyclines remain “evergreen” drugs with broad clinical indications but have still an improvable therapeutic index.